This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Palatability Testing of a New Paediatric Formulation of Valacyclovir (VALID-0)

This study has been completed.
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by (Responsible Party):
Radboud University Identifier:
First received: September 5, 2012
Last updated: May 24, 2016
Last verified: January 2016
Palatability testing of a new paediatric formulation of valacyclovir in children 4-12 years of age and at least one of their parents. Children will be included, who received (val)acyclovir prophylaxis in the past, or will probably need it in the future i.e. children with primary immune deficiency or cancer.

Condition Intervention Phase
Varicella Zoster Virus Infection Herpes Simplex Virus Infection Drug: Valacyclovir Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children

Resource links provided by NLM:

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Selection of oral solution with best taste [ Time Frame: Day 1 ]
    Patients (children) will assess the taste of 3 different oral solutions. A questionnaire has to be completed to order the palatability of the three formulations.

Secondary Outcome Measures:
  • Taste assessment [ Time Frame: Day 1 ]
    Children will score the taste of 3 different oral valacyclovir solutions. A 100 mm facial hedonic scale will be employed to indicate the palatability of each formulation.

  • Predictability of palatability preference of the child by parents. [ Time Frame: Day 1 ]
    To determine whether parents can predict the palatability preference of their child.

Enrollment: 41
Study Start Date: September 2012
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: new paediatric valacyclovir formulation
Newly developed formulation
Drug: Valacyclovir
Other Name: valacyclovir solution
Active Comparator: reference valacyclovir formulation
Formulation derived from FDA label information
Drug: Valacyclovir
Other Name: valacyclovir solution


Ages Eligible for Study:   4 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject is at least 4 years of age.
  • Subject weighs at least 15kg.
  • Subject is capable of performing the taste assessment, according to the investigator's judgement.
  • The child and parent(s) are willing to participate in the taste assessment.
  • Signed informed consent by the legal guardian for participation of the child and if the parent also wants to participate: signed informed consent for their own participation, prior to start of the study.

Exclusion Criteria:

  • Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
  • Presence of any condition that influences taste sensation (such as upper respiratory infection, febrile illness within 3 days before the first dose, mucositis or use of medication that influences taste perception, as described in the label information).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01682109

Radboud University Medical Center
Nijmegen, Netherlands
Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Principal Investigator: David Burger Radboud University
  More Information

Responsible Party: Radboud University Identifier: NCT01682109     History of Changes
Other Study ID Numbers: UMCN-AKF 11.05
Study First Received: September 5, 2012
Last Updated: May 24, 2016

Keywords provided by Radboud University:
herpes zoster
herpes simplex

Additional relevant MeSH terms:
Communicable Diseases
Virus Diseases
Herpes Simplex
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases
Antiviral Agents
Anti-Infective Agents processed this record on September 21, 2017